NCT06787430Not yet recruitingPhase 4
Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI
Evaluating the Effects of Nicorandil on Microvascular Dysfunction in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately one half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, namely microvascular dysfunction. Previous studies have shown that coronary microvascular damage significantly impacts the prognosis of patients with STEMI. Therefore, restoration of microvascular function is quite important during the PPCI procedures. Recent clinical trials found that nicorandil, a hybrid ATP-sensitive potassium channel opening agent, improved microvascular function, prevented no-reflow phenomenon, and had beneficial cardioprotective effects in patients receiving PPCI. However, there was a lack of evidence on the protective effects of nicorandil on microvascular function. The coronary angiography-derived IMR (AMR) is a novel wire-free technology developed for fast computation of IMR in patients undergoing coronary angiography, thereby enabling the quantification of coronary microcirculation of patients. This study is aimed to investigate the effects of nicorandil on microvascular dysfunction as evaluated by AMR in patients with STEMI.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- First submitted
- 26 Dec 2024
- Start date
- 1 Mar 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Coronary artery disease
- NCT number
- NCT06787430
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 170
- From 1 Mar 2026 to the primary completion date, 1 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute in- stent thrombosis or in-stent stenosis lesions of culprit vessel.
- Allergic to nicorandil or systolic arterial pressure was less than 85mmHg before procedure
- Cardiac shock needing mechanical support.
- Severely renal failure needing hemodialysis.
Other
- Balloon angioplasty rather than stent was planned for the culprit vessel.
- Vessel with twisted shape that was unable to be measured using AMR
- Oral or intravenous use of nicorandil within one month.
- Severely hepatic dysfunction.
- Contraindicated for coronary angiography or primary PCI.
- Culprit vessels of left main or graft vessels.
- Pregnant or nursing.
- Others that investigators think should excluded.
Who the study is looking for
- Age between 18-80
- Diagnosis of STEMI and indicating for primary PCI
- Diagnostic coronary angiography showed definite culprit vessel and primary PCI was planned to treat the culprit vessel.
- Reference vessel diameter of culprit vessel was greater than 2.0 mm
- There was no flow-limiting stenosis for the non-culprit vessels.
- Understand the aim of this trial and agree to sign the informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.